Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Nasal Glucagon in Diabetes
NCT02806973Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of glucagon in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to T(AUC[0-tlast]) of Baseline-Adjusted Glucagon, Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon and 4 more. Started Jan 2015; status: completed.
02
Drugs
glucagon
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02806973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806973.